



Medical Policy Reference Manual Medical Policy

5.01.044 Lutetium vivopitide tetraxetan (Pluvicto™)

Original MPC Approval: 08/01/2022

Last Review:

Last Revision:

Description

Metastatic castration-resistant prostate cancer is an incurable and fatal condition. Treatments for this condition seek to delay progression and prolong life. Metastatic lesions are positive for Prostate-specific Membrane Antigen (PSMA) in most patients with castration-resistant prostate cancer. When prostate cancer becomes metastatic hormone treatments no longer work at controlling cancer growth and cancer is found in tissues beyond the prostate.

Chemotherapy is traditionally used when prostate cancer has spread outside the prostate gland and hormone therapy is no longer working. Chemotherapy involves the use of chemicals to kill or halt the growth of cancer cells. Side effects of chemotherapy vary on an individual basis, but they may include hair loss, mouth sores, nausea and vomiting, loss of appetite, and increased risk of infection.

Radioligand therapy delivers radiation directly to target cells. The mechanism behind the targeted delivery involves binding a small dose of radiation to a molecule that specifically binds to prostate cancer cells. The direct delivery of radiation to cancerous cells has been found to reduce toxic effects and enhance treatment efficacy.

Policy

There is no policy statement for this policy.

Policy Guidelines

<https://provider.carefirst.com/providers/pharmacy/pharmacy-forms.page>

Benefit Applications

NOTE: For FEP business, check member's contract for benefits.

Provider Guidelines

Prior pharmacy authorization is required for Lutetium 177 (Lu 177) vipivotide tetraxetan (Pluvicto™). Providers should submit preauthorization requests online at provider.carefirst.com or call 1-866-773-2884 (1-866-PRE-AUTH).

Cross References to Related Policies and Procedures

There are no Related Policies for this Medical Policy.

References

The following were among the resources reviewed and considered in developing this policy. By reviewing and considering the resources, CareFirst does not in any way endorse the contents thereof nor assume any liability or responsibility in connection therewith. The opinions and conclusions of the authors of these resources are their own and may or may not be in agreement with those of CareFirst.

Dawson, N.A. and Leger, P. (June 16, 2022) Overview of the treatment of castration-resistant prostate cancer (CRPC), *UpToDate*, https://www.uptodate.com/contents/overview-of-the-treatment-of-castration-resistant-prostate-cancer-crpc?search=pluvicto&source=search_result&selectedTitle=2~5&usage_type=default&display_rank=1.

Food and Drug Administration, Prescribing Information for PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan) injection, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf.

Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T.,

National Comprehensive Cancer Network® (May 10, 2022) Prostate Cancer, version 4.2022, https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

Vaishampayan, N., El-Haddad, G., Park, C. H., Beer, T. M., Armour, A., Pérez-Contreras, W. J., DeSilvio, M., Kpamegan, E., Gericke, G., Messmann, R. A., Morris, M. J., Krause, B. J., ... VISION Investigators (2021). Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. *The New England journal of medicine*, 385(12), 1091–1103. <https://doi.org/10.1056/NEJMoa2107322>

Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., Park, C. H., Beer, T. M., Armour, A., Pérez-Contreras, W. J., DeSilvio, M., Kpamegan, E., Gericke, G., Messmann, R. A., Morris, M. J., Krause, B. J., ... VISION Investigators (2021). Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. *The New England journal of medicine*, 385(12), 1091–1103. <https://doi.org/10.1056/NEJMoa2107322>

This policy statement relates only to the services or supplies described herein. Coverage will vary from contract to contract and by line of business and should be verified before applying the terms of the policy.